Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Holdings -- Ignore unavailable to you. Want to Upgrade?

To: Mike Heimbuch who wrote (82)	12/8/1997 2:39:00 PM
From: jacq	Read Replies (1) \| Respond to of 224

Did you hear that Glaxo-Wellcome pulled the drug troglitazone brand name Romozin from the market in Britain. "after growing increasingly concerned over toxic side effects and six deaths in the United States and Japan,"???? Sales for Warner Lambert were $137 million in the third quarter. When Glaxo pulled the drug the stock price of WL fell 18.5% Whenever I have talked to management they have stated that they have no big concerns about a financial squeeze that they have sources of cash and have a partner very ready to sign on. This has always been my biggest concern. If the medication works as well as it is said to and if it is as safe I would be absolutely amazed if a large drug company didn't make a buyout offer. The stock is trading for pennies now even with the major shareholder blocks a drug company could pick up 40-50% for peanuts. Thanks for the post and have some good holidays. Jacques